New understanding of cellular activity can lead to future strategies for dealing with neurodegenerative diseases, say Hebrew U. researchers


Dr. Daniel KaganovichDecember 6, 2012: A new understanding of what takes place on the cellular level during the development of neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, ALS and Huntington’s diseases, offers promise towards possible new strategies for combating such diseases, say Hebrew University of Jerusalem researchers.

Neurodegenerative conditions result from an impairment of motor function or cognitive function or both. This impairment results from degeneration in the particular area of the brain responsible for those functions.

Although these neurodegenerative diseases have been functionally linked to toxic protein aggregation (deposits), there is much that is unknown about the mechanism through which aggregation causes toxicity and death at the cellular level. Inclusion bodies — structures comprised of pathogenic protein aggregates — have long been seen as a hallmark of disease, but the relationship between inclusions and disease has remained somewhat mysterious.

In a study published in PNAS (Proceedings of the National Academy of Sciences), Hebrew University researchers in the lab of Dr. Daniel Kaganovich in the Department of Cell and Developmental Biology in the Silberman Institute of Life Sciences, together with collaborators, present evidence that suggests that these inclusion bodies, which have traditionally been thought to accompany disease onset, actually have a cell-biological function that is not necessarily related to the disease conditions.

Further, the researchers suggest that some of those inclusion bodies not only are not toxic, but actually are part of a natural protective process. The researchers have identified two inclusion bodies, which they call JUNQ and IPOD. Aggregation in the JUNQ can lead to toxicity, whereas aggregation in the IPOD is protective.

These findings, say the Hebrew University researchers, point to a new potential strategy for designing therapeutics for neurodegenerative diseases. Instead of preventing proteins from aggregating, which can be very difficult, it may be possible to enhance the cellular ability to actively enclose harmful aggregates within protective inclusions, thereby neutralizing the toxic proteins that bring on further neurodegenerative damage and even death.

Harvard graduate Dr. Daniel Kaganovich, who joined the Hebrew University in 2010, is exploring protein folding and aggregation.

Source: Dept. Media Relations, Hebrew University